Esther Cubo, MDS 2022: Insulin-like growth factor-1 and social cognition in Huntington’s disease
This study in patients with Huntington’s disease aimed to assess insulin-like growth factor-1 (IGF-1) levels and hypothalamic function, and the association with non-motor symptoms and brain structure. In this touchNEUROLOGY interview, we speak with Dr Esther Cubo (Hospital Universitario de Burgos, Burgos, Spain) to discuss the study, its findings and future studies that are planned.Â
The abstract entitled ‘Association between Insulin-Like Growth Factor-1 and Social Cognition in Huntington’s Disease’ was presented at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain, 15 – 18 September 2022.
Questions:
- What is known about the association between insulin-like growth factor-1 and social cognition in Huntington’s Disease (HD)? (0:18)
- What were the objectives and methodology of your study? (0:59)
- What differences in plasma and urine were found between the HD group and controls? (2:29)
- What associations were found between IGF-1 and brain structure? (3:44)
- How do these findings add to our knowledge of the role of IGF-1 in HD, and what future studies are planned? (4:08)
Disclosures: Esther Cubo has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of MDS 2022
Access more content on Huntington’s Disease here
